CNAT - Conatus Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.3859
+0.0128 (+3.43%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.3731
Open0.3877
Bid0.0000 x 1300
Ask0.0000 x 900
Day's Range0.3716 - 0.4000
52 Week Range0.2500 - 6.7400
Volume611,988
Avg. Volume1,256,912
Market Cap12.8M
Beta (3Y Monthly)2.23
PE Ratio (TTM)N/A
EPS (TTM)-0.4350
Earnings DateAug 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.60
Trade prices are not sourced from all markets
  • Top Ranked Momentum Stocks to Buy for September 10th
    Zacks

    Top Ranked Momentum Stocks to Buy for September 10th

    Top Ranked Momentum Stocks to Buy for September 10th

  • Conatus (CNAT) Upgraded to Strong Buy: Here's What You Should Know
    Zacks

    Conatus (CNAT) Upgraded to Strong Buy: Here's What You Should Know

    Conatus (CNAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).

  • Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies
    Zacks

    Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies

    Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.

  • Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Tops Revenue Estimates

    Conatus (CNAT) delivered earnings and revenue surprises of 83.33% and 54.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Conatus Pharmaceuticals Reports Second Quarter 2019 Financial Results and Program Updates

    SAN DIEGO, Aug. 06, 2019 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the quarter and six months ended June 30, 2019, and provided.

  • Will Conatus Pharmaceuticals (CNAT) Report Negative Q2 Earnings? What You Should Know
    Zacks

    Will Conatus Pharmaceuticals (CNAT) Report Negative Q2 Earnings? What You Should Know

    Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Investors Who Bought Conatus Pharmaceuticals (NASDAQ:CNAT) Shares Five Years Ago Are Now Down 96%
    Simply Wall St.

    Investors Who Bought Conatus Pharmaceuticals (NASDAQ:CNAT) Shares Five Years Ago Are Now Down 96%

    Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shareholders should be happy to see the share price up 21% in the last...

  • Conatus (CNAT) Stock Price Could Hit Zero
    SmarterAnalyst

    Conatus (CNAT) Stock Price Could Hit Zero

    Did an iceberg just wallop into Conatus (CNAT) stock? This biotech company's shares plunged yesterday at breakneck speed of almost 70%. The reason? Conatus’ lead drug Emricasan failed a mid-stage trial in patients with nonalcoholic steatohepatitis-related decompensated cirrhosis.Emricasan – an oral pan-caspase inhibitor that targets nonalcoholic steatohepatitis – has gone through several trials over the last three years. This recent phase 2b trial was conclusive enough for Conatus to forgo any further testing, after the trial clearly proved the drug is not an effective treatment.Amidst uncertainty about Conatus’ strategic options, H.C. Wainwright analyst Ed Arce has removed his price target on CNAT stock, while maintaining a Neutral rating. (To watch Arce's track record, click here)Conatus projects its cash and equivalents at the end of 2019 to be in the range of $10M to $15M. The company also announced that 40% of their staff were laid off after the failure and suspension of the 2b trial.Arce believes that it is incredibly challenging to value the company during this period of cash preservation and strategic re-evaluation. With the termination of the development program for Emricasan, Conatus is currently focused on finding a strategic purchaser who sees value in the CTS-2090 compound used in Emricasan and the expertise of the remaining employees. With a market cap of $9.64M, it appears that the market is pricing in the possibility of bankruptcy, as the company is being valued below Conatus’ projections of end-of-year 2019 cash and equivalents.Arce believes the main concern is that if the company cannot find a strategic acquirer before their cash runs dry, they are at seriously risk of going into bankruptcy.TipRanks suggests caution roars loud on Wall Street for sell-side analysts sizing up the challenged drug maker's prospects. Out of 4 analysts polled in the last 12 months, all 4 are sidelined on CNAT stock. (See CNAT's price targets and analyst ratings on TipRanks) More recent articles from Smarter Analyst: * Qualcomm (QCOM): 3 Takeaways From Deutsche Bank Tech Conference * Is 33% Upside Good Enough to Risk Buying Fitbit (FIT) Stock? Deutsche Bank Doesn't Think So * Deutsche Bank Remains Sidelined on AMD Stock; Here's Why * Antitrust Investigation Is Not a Major Threat to Alphabet (GOOGL) Stock, Says Top Analyst

  • Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
    Zacks

    Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • Benzinga

    The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ...

  • Conatus' Emricasan Lags Primary Goal in Liver Function Study
    Zacks

    Conatus' Emricasan Lags Primary Goal in Liver Function Study

    Conatus' (CNAT) emricasan fails to meet the primary endpoint in the phase IIb ENCORE-LF study on decompensated NASH cirrhosis patients while the ENCORE-PH probe falls shy of the predefined objectives.

  • Benzinga

    NASH Disappointment Forces Conatus To Explore Strategic Alternatives

    Shares of micro-cap biotech Conatus Pharmaceuticals Inc (NASDAQ: CNAT) were sinking further into penny stock territory Tuesday after two announcements made Monday after the market close. Conatus said it has engaged Oppenheimer to explore strategic alternatives in a bid to enhance shareholder value.

  • Reuters

    UPDATE 1-Conatus Pharma to explore options as liver disease drug fails trial

    Conatus Pharmaceuticals Inc said on Monday it plans to explore options and implement a restructuring plan after its liver disease drug failed in a mid-stage trial. The drug was being developed to treat patients with nonalcoholic steatohepatitis (NASH), a fatty liver disease where fat accumulation and inflammation can lead to scarring, or fibrosis, that impairs liver function. Novartis AG in 2017 had exercised its option with Conatus to develop emricasan.

  • GlobeNewswire

    Conatus to Explore Strategic Alternatives and Implement Restructuring Plan

    Conatus Pharmaceuticals Inc. (CNAT) today announced that the company has engaged Oppenheimer & Co., Inc., as its financial advisor to assist in the exploration and evaluation of strategic alternatives to enhance shareholder value. In order to extend its resources, Conatus is implementing a restructuring plan that includes reducing staff by approximately 40% and suspending development of its inflammasome disease candidate, CTS-2090. The company has updated its financial guidance and is projecting a year-end 2019 net balance of cash, cash equivalents and marketable securities of between $10 million and $15 million.

  • GlobeNewswire

    Conatus Announces Results from ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Cirrhosis

    Conatus Pharmaceuticals Inc. (CNAT) today announced that top-line results from the company’s ENCORE-LF clinical trial of emricasan did not meet its primary endpoint and the company is discontinuing further treatment of patients enrolled in the ENCORE-LF clinical trial.  Also, results from the 24-week extension in the company’s ENCORE-PH clinical trial of emricasan were consistent with results from the initial 24-week treatment period and did not meet predefined objectives. Conatus will continue to work with its partner Novartis on ensuring that all remaining obligations related to the emricasan program are fulfilled. The randomized, double-blind ENCORE-LF Phase 2b clinical trial, initiated in the second quarter of 2017, enrolled 217 patients with decompensated NASH cirrhosis.

  • CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study
    Zacks

    CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study

    CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat.

  • Conatus (CNAT) Down 5.8% Since Last Earnings Report: Can It Rebound?
    Zacks

    Conatus (CNAT) Down 5.8% Since Last Earnings Report: Can It Rebound?

    Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Conatus Down More Than 60% in the Past 90 Days: Here's Why
    Zacks

    Conatus Down More Than 60% in the Past 90 Days: Here's Why

    Conatus' (CNAT) lead candidate, emricasan, developed for treating patients with fibrosis or cirrhosis caused by NASH misses the primary endpoint in two mid-stage studies that hits the stock massively.

  • How Many Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Shares Do Institutions Own?
    Simply Wall St.

    How Many Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Shares Do Institutions Own?

    Every investor in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) should be aware of the most powerful shareholder groups...

  • Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1
    Zacks

    Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1

    Conatus, (CNAT) earnings and revenues lag estimates in the first-quarter of 2019. Emricasan remains in focus.

  • Conatus Pharmaceuticals (CNAT) Reports Q1 Loss, Lags Revenue Estimates
    Zacks

    Conatus Pharmaceuticals (CNAT) Reports Q1 Loss, Lags Revenue Estimates

    Conatus (CNAT) delivered earnings and revenue surprises of -16.67% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    Conatus: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 14 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire

    Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis

    Conatus Pharmaceuticals Inc. (CNAT) today announced a new publication1 in Hepatology Communications detailing results following seven-day treatment with emricasan, the company’s first-in-class pan-caspase inhibitor, in rats with advanced cirrhosis including increased portal pressure induced by chronic carbon tetrachloride administration. Portal pressure was significantly reduced in emricasan-treated rats relative to vehicle-treated control animals. Reduced portal pressure was associated with significantly better liver function, reduced liver inflammation, and reduced fibrosis.

  • Conatus Pharmaceuticals (CNAT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zacks

    Conatus Pharmaceuticals (CNAT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension

    Conatus Pharmaceuticals Inc. (CNAT) announced today that the company’s late-breaker oral presentation at The International Liver Congress™ 2019, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 10-14, was also selected by EASL for inclusion in the “Best of ILC” summary slide deck highlighting the most noteworthy contributions to the scientific program at this year’s meeting. The oral presentation at EASL entitled, “Multicenter, Double-blind, Placebo-controlled, Randomized Trial of Emricasan in Subjects with NASH Cirrhosis and Severe Portal Hypertension (PH),” (#LB01) detailed results from the company’s Phase 2b ENCORE-PH clinical trial of emricasan, the company’s first-in-class, orally active pan-caspase protease inhibitor.